Granules India Limited Earnings Summary — Q4 FY2026
Granules India Delivers Record Quarterly Performance with 23% Sales Growth and Significant Margin Expansion
Key Takeaways
- Achieved record quarterly sales of ₹1,471 Cr, representing a 22.9% year-on-year increase.
- Operating margins expanded to 24%, the highest in recent fiscal years, driven by improved product mix and scale.
- Net profit surged to ₹202 Cr, a 33% increase over the previous year, supported by record quarterly topline performance.
- Aggressive capital expenditure continues with fixed assets increasing significantly to ₹3,253 Cr in FY2026.
- Interest costs remain elevated at ₹33 Cr for the quarter due to increased borrowing for capacity expansion.
- Strong vertical integration in core molecules like Paracetamol and Metformin continues to drive volume growth.
- The company is successfully transitioning toward higher-value finished dosage segments away from simple APIs.
Management Guidance
Management is focused on maintaining global leadership in core molecules while scaling complex generics and high-margin finished dosages through aggressive capex and vertical integration.
Sentiment Shift
Improving
Outlook
The outlook is optimistic as massive Capital Work-in-Progress (CWIP) begins to convert into operational fixed assets, likely improving asset turnover and justifying recent heavy investments.
← Back to Granules India Limited AI analysis
Unlock the full report
Deep-dive sections, financial charts, AI chat and PDF export are available with Premium.
This summary is AI-generated from Granules India Limited's latest annual report and public disclosures. It is for informational purposes only and is not investment advice.